# A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

> **NCT05732103** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chordia Therapeutics, Inc.** · enrollment: 225 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** CTX-712

## Key facts

- **NCT ID:** NCT05732103
- **Lead sponsor:** Chordia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2028-06
- **Final completion:** 2029-02
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732103, "A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05732103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*